EDO-S101 for MGMT Unmethylated Glioblastoma (nGBM)

You may be eligible for inclusion in the above clinical trial, which is being conducted at the MD Anderson Cancer Center in Texas in the USA. The aim of the study is to examine the effects of the novel treatment tinostamustine in those patients with certain types of brain cancer who do not respond to alternative therapies.

If you wish to be considered for this study, you should contact your healthcare professional and they will assess your suitability and if appropriate, refer you to the centre undertaking the trial.

To take part in this trial, you will have to meet certain requirements, which include: Age ≥18 years, that you are not currently pregnant and/or breastfeeding and that you have not recently participated in a clinical trial.

Study of EDO-S101, A First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies

You may be eligible for inclusion in the above clinical trial, which has study centres in Arizona, Florida, and New York in the USA and in Heidelberg, Cologne, Bologna, Naples, and St Gallen in Europe. The aim of the study is to examine the effects of the novel treatment tinostamustine in those patients with certain blood cancers who have failed previous therapies.

If you wish to be considered for this study, you should contact your healthcare professional and they will assess your suitability and if appropriate, refer you to the centre undertaking the trial.

To take part in this trial, you will have to meet certain requirements, which include: Age ≥18 years, that you are not currently pregnant and/or breastfeeding and that you have not recently participated in a clinical trial.

Study of the Safety, Pharmacokinetics and Efficacy of EDO-S101, in Patients With Advanced Solid Tumors

You may be eligible for inclusion in the above clinical trial, which has study centres in Arizona and California in the USA. The aim of the study is to examine the effects of the novel treatment tinostamustine in those patients with certain types of cancer who have failed previous therapies.

If you wish to be considered for this study, you should contact your healthcare professional and they will assess your suitability and if appropriate, refer you to the centre undertaking the trial.

To take part in this trial, you will have to meet certain requirements, which include: Age ≥18 years, that you are not currently pregnant and/or breastfeeding and that you have not recently participated in a clinical trial.

Tinostamustine Conditioning and Autologous Stem Cell (TITANIUM1)

You may be eligible for inclusion in the above clinical trial, which has study centres in Alabama, Kansas, New York, North Carolina, Tennessee, Texas, and Wisconsin in the USA and in Oslo, Basel, Bern, St Gallen, and Zurich in Europe. The aim of the study is to examine the effects of the novel treatment tinostamustine as conditioning therapy for those patients with relapsed or progressive multiple myeloma who are eligible to receive a second autologous stem cell transplant.

If you wish to be considered for this study, you should contact your healthcare professional and they will assess your suitability and if appropriate, refer you to the centre undertaking the trial.

To take part in this trial, you will have to meet certain requirements, which include: Age range of 18-75 years, that you have received a previous stem cell transplant, that you are not currently pregnant and/or breastfeeding and that you have not recently participated in a clinical trial.

Unfortunately, you are not eligible

Thank you for your interest in Mundipharma EDO’s clinical trials. Unfortunately, we do not currently have any trials for which you would be eligible. Please consult your healthcare professional for details of other clinical trials that may be suitable for you